Keystone Heart is a Caesarea, Israel-based medical device company focused on cerebral protection for cardiovascular interventions. Its lead product, the CE-marked TriGuard™ Cerebral Protection Device, is designed to provide full coverage to all aortic arch takeoffs and protect all brain territories. The device is intended to minimize the risk of cerebral damage during TAVR and other cardiovascular procedures. Keystone Heart closed $14M in Series B financing led by OrbiMed to advance clinical development. The company will use the funds to conduct a European multi-center, randomized clinical trial during TAVR procedures and to support a planned FDA IDE study. It is planning additional studies to leverage the TriGuard product pipeline and generate clinical data to support global commercialization; TriGuard is not yet commercially available in the USA.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

May 2014